Goldman Sachs Call 100 SNW 17.01..../ DE000GJ5WD72 /
1/9/2025 10:11:59 AM | Chg.-0.003 | Bid5:12:46 PM | Ask5:12:46 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.030EUR | -9.09% | 0.036 Bid Size: 50,000 |
0.046 Ask Size: 50,000 |
SANOFI SA INHABER ... | 100.00 EUR | 1/17/2025 | Call |
GlobeNewswire
9/2/2024
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to ...
GlobeNewswire
8/26/2024
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire
8/14/2024
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
GlobeNewswire
8/13/2024
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
8/12/2024
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter ...
GlobeNewswire
8/8/2024
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free sur...
GlobeNewswire
8/7/2024
Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
8/6/2024
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D ...
GlobeNewswire
8/1/2024
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
7/31/2024
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2...
GlobeNewswire
7/25/2024
Press Release: Online availability of Sanofi’s half-year financial report for 2024
GlobeNewswire
7/25/2024
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded